Publication

What would a Brexit mean for IP rights?

What would a Brexit mean for IP rights?

By , and | 31 Mar 2016

How would a Brexit affect the way that businesses are able to protect and enforce their Intellectual Property rights in the UK?

Publication

To patent or not to patent, is that the question?

To patent or not to patent, is that the question?

By | 10 Mar 2016

Should a company file a patent or rely on trade secrets as a form of protection?

Publication

Of mice and patents — Kymab beats Regeneron for insufficiency

Of mice and patents — Kymab beats Regeneron for insufficiency

By | 16 Feb 2016

Key points and lessons from Regeneron Pharmaceuticals Inc. v. Kymab

Publication

Revolutionising genome editing with CRISPR/Cas9: patent battles and human embryos

Revolutionising genome editing with CRISPR/Cas9: patent battles and human embryos

By | 18 Dec 2015

Beatriz San Martin and Hannah Smith Willis write for Cell & Gene Therapy Insights.

Publication

CJEU clarifies application of the Specific Mechanism

CJEU clarifies application of the Specific Mechanism

By | 09 Apr 2015

In 12 February 2015, the Court of Justice of the European Union (CJEU) delivered its decision on the questions referred to it by the Court of Appeal on the interpretation of the Specific Mechanism.

Publication

IPEC damages cap of £500,000 does not apply separately to each defendant in an action where there are multiple defendants

IPEC damages cap of £500,000 does not apply separately to each defendant in an action where there are multiple defendants

30 Oct 2014

Mr Justice Birss ruled that the IPEC damages cap of £500,000 as set out in CPR 63.17A is to apply to all defendants in a single action and not in relation to each defendant.

Publication

Major reforms in the IP world today (and still more to come…)

Major reforms in the IP world today (and still more to come…)

By | 01 Oct 2014

Changes to design and patent law: implementation of a number of design and patent provisions in the IPA 2014 come into force today.

Publication

What is Common General Knowledge?

What is Common General Knowledge?

11 Sep 2014

Teva has successfully revoked a patent owned by AstraZeneca for the treatment of asthma for lack of inventive step.

Publications RSS